Related Experiment Video

Updated: May 29, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Inhibitor of MEK1/2, selumetinib, for biliary tract cancer

Junji Furuse1, Fumio Nagashima

  • 1Department of Internal Medicine, Medical Oncology, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo, 181-8611, Japan. jfuruse@ks.kyorin-u.ac.jp

Expert Review of Gastroenterology & Hepatology
|September 14, 2011
PubMed

Insights

This Phase II study investigated selumetinib for metastatic biliary cancer. While showing a 12% response rate and manageable side effects, further research is needed for this targeted therapy.

Area of Science:

  • Oncology
  • Medical Research
  • Pharmacology

Background:

  • Biliary tract cancer (BTC) demands improved chemotherapy options for patient survival.
  • Current molecular-targeted agents show limited efficacy as first-line treatments for advanced BTC.

Discussion:

  • Selumetinib, a MEK1/2 inhibitor targeting the RAS/RAF/MEK/ERK pathway, was evaluated in a Phase II study for metastatic BTC.
  • The study observed a 12% partial response rate (3/28 patients), with median progression-free survival of 3.7 months and overall survival of 9.8 months.

Key Insights:

  • Selumetinib demonstrated a modest response rate in metastatic biliary cancer patients.
  • Common toxicities included rash, dry mouth, and nausea, mostly grade 1/2, with manageable grade 3/4 diarrhea and nausea.

Outlook:

  • The observed efficacy and manageable toxicity profile suggest selumetinib warrants further investigation in metastatic biliary cancer.
  • Future studies may explore selumetinib's role in combination therapies or specific patient subgroups.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...